

Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC)

PROJECT BRIEF
OCTOBER 2021

Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021-2026) global project funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID) to help women prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products.

MOSAIC will work across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products.



Photo Credit: OPTIONS consortium

The MOSAIC consortium is led by FHI 360 along with core partners Wits Reproductive Health and HIV Institute (Wits RHI), Pangaea Zimbabwe AIDS Trust (PZAT), LVCT Health, Jhpiego, and AVAC. Local partner leadership and engagement, particularly in sub-Saharan Africa, is intrinsic to the project's approach to expediting women's access to new HIV prevention products. The work will also be supported by technical partners from Afton Bloom, Avenir Health, Columbia University, Mann Global Health, RTI International, the University of Pittsburgh, and the University of Washington.

Working closely with product developers, MOSAIC will advance access to and uptake within a multi-product market that includes options such as oral pre-exposure prophylaxis (oral PrEP), the dapivirine ring (also called PrEP ring), and injectable long-acting cabotegravir (CAB PrEP). Proposed priority countries for the consortium's work are Kenya, South Africa, Zambia, and Zimbabwe, with additional efforts in Eswatini, Lesotho, and Uganda.

Project Objective and Approach

MOSAIC's objective is to accelerate introduction and scale-up of new biomedical prevention products and expedite their availability, acceptance, uptake, and impact in PEPFAR programs to help individuals, especially women, prevent HIV and other infectious diseases. To achieve this objective, MOSAIC will work in alignment with five strategic priorities:

Promote a **user-centered approach** in which the needs and preferences of users — especially adolescent girls and young women — are understood and addressed in product introduction and scale-up

Conduct **research to expand the evidence base** on how to effectively enhance product availability, acceptability, uptake, and effective use

Coordinate and provide technical assistance to global, national, and subnational stakeholders to **expedite product introduction in policy and programs** by addressing issues related to regulatory review, policy development, resource mobilization, supply chain, delivery models and platforms, monitoring and evaluation, surveillance, and demand generation

Implement **research utilization** activities and establish mechanisms for **rapid, effective knowledge exchange** among key stakeholders to facilitate application of existing and emerging evidence on product introduction in policy and programs

Strengthen and sustain local partner capacity to advocate for, design, and implement high-quality product introduction activities and research

What MOSAIC Means for Women

Our vision is that after five years, women in sub-Saharan Africa will have access to multiple effective PrEP products that meet their changing needs and desires; that health systems will be enabled to support informed choice and effective use through policies, programming, and differentiated service delivery; and that cost, impact, and targeting guidance will be in place to support efficient use of resources.

For more information about MOSAIC, please contact:

- Kristine Torjesen, MOSAIC Project Director, FHI 360: ktorjesen@fhi360.org
- Ashley Vij, USAID/Office of HIV/AIDS: avij@usaid.gov